MTOR and diffuse large B-cell lymphoma: Aberrant activation of the PI3K/AKT/mTOR pathway has been observed in critical subgroups of DLBCL samples, driven by chronic BCR signaling activation or loss of expression of phosphatases and PTEN (Xu et al. 2023).